Investigational Drug Details
| Drug ID: | D248 |
| Drug Name: | Prednisolone |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00860 |
| DrugBank Description: | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431] |
| PubChem ID: | 5755 |
| CasNo: | 50-24-8 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |
| Structure: |
|
| InChiKey: | OIGNJSKKLXVSLS-VWUMJDOOSA-N |
| Molecular Weight: | 360.444 |
| DrugBank Targets: | Glucocorticoid receptor |
| DrugBank MoA: | The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463] Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463] Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463] |
| DrugBank Pharmacology: | Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisolone has a short duration of action as the half life is 2.1-3.5 hours.[A187394] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463] |
| DrugBank Indication: | Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0017 | NCT00308490 | PHASE4 | COMPLETED | NO | 2005-09 | 2007-03-13 | Details |
| L0346 | NCT02258074 | PHASE2 | COMPLETED | YES | 2015-03 | 2021-08-02 | Details |
| L0350 | NCT04925661 | PHASE1 | UNKNOWN | NO | 2021-09-29 | 2021-06-24 | Details |
| L0493 | NCT04515849 | PHASE2 | COMPLETED | YES | 2020-08-31 | 2025-01-17 | Details |
| L1208 | NCT06608212 | ACTIVE_NOT_RECRUITING | NO | 2024-10-09 | 2025-04-11 | Details | |
| L1995 | NCT03102476 | COMPLETED | NO | 2016-06 | 2018-10-31 | Details | |
| L2525 | NCT00909480 | PHASE4 | COMPLETED | YES | 2009-05 | 2017-03-10 | Details |
| L2564 | NCT00476710 | COMPLETED | NO | 2007-05 | 2015-04-01 | Details | |
| L2577 | NCT01217112 | PHASE2 | COMPLETED | YES | 2010-10 | 2022-10-18 | Details |
| L3823 | NCT06411210 | PHASE2 | RECRUITING | NO | 2024-07-16 | 2024-07-23 | Details |
| L6110 | NCT05095922 | PHASE4 | COMPLETED | NO | 2023-03-28 | 2024-07-09 | Details |
| L6925 | NCT04307797 | PHASE4 | COMPLETED | NO | 2022-01-18 | 2024-09-19 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|